|Bid||10.65 x 100|
|Ask||13.00 x 300|
|Day's Range||11.04 - 11.32|
|52 Week Range||4.88 - 12.04|
|PE Ratio (TTM)||15.54|
|Earnings Date||Jun 9, 2017 - Jun 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Q3 2017 Enzo Biochem Inc Earnings Call
Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.